Integrated photomedical treatment of skin tumor-associated hereditary dermatoses

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036170

Enrollment

Unknown

Registered

2020-08-21

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin tumor-associated hereditary dermatosis

Interventions

Tuberous sclerosis with facial angiofibroma:Laser combination therapy

Tuberous sclerosis with periarmour fibroma: Laser combination therapy

Syringoma:Laser combination therapy

Verrucous epidermal dysplasia with plant-like skin lesions:Laser combination therapy

Pigmented xeroderma and/or verrucous epidermal dysplasia with seborrheic keratosis:Laser combination therapy

Xeroderma pigmentosum and/or verrucous epidermal dysplasia with sunspots:Laser combination therapy

Pigmented xeroderma and/or verrucous epidermal dysplasia accompanied by actinic keratosis:ALA-PDT

Pigmented xeroderma and/or verrucous epidermal dysplasia accompanied by cutaneous squamous cell carcinoma:ALA-PDT

Pigmented xeroderma and/or verrucous epidermal dysplasia with basal cell carcinoma:ALA-PDT

Neurofibromatosis type 1 complicated by cutaneous neurofibroma:Laser combination therapy

Neurofibromatosis type 1 complicated by cutaneous plexus neurofibroma:Laser combination therapy

Xeroderma pigmentosum and/or verrucous epidermal dysplasia with advanced non-melanin skin cancer:Laser and ALA-PDT combination therapy

Pigmented xeroderma and/or verrucous epidermal dysplasia with associated skin cancer:Laser and ALA-PDT combined standardized treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Gender, age and course of disease are not limited 2. A definite diagnosis of tuberous sclerosis with facial angiofibroma and perinail fibroma.Type 1 neurofibromatosis is accompanied by cutaneous neurofibroma and plexiform neurofibroma.Vulvar syringomas.Patients with verrucous epidermal dysplasia accompanied by plana verrucous dermatitis 3. A genetic diagnosis of xeroderma pigmentosum or verrucous epidermal dysplasia with actinic keratosis, cutaneous squamous cell carcinoma, or basal cell carcinoma lesions was confirmed by skin biopsy 4. After full explanation of the purpose and content of the clinical trial (including subjects' compliance, etc.), participants shall voluntarily participate in and sign informed consent on the basis of full understanding

Exclusion criteria

Exclusion criteria: 1. Patients with absolute contraindications to surgery. 2. All types of laser or ALA-PDT treatments and any other impact studies performed within 12 weeks. 3. Combined with other diseases that may affect the efficacy evaluation, such as other photosensitive skin diseases. 4. Those who take phototoxic or photosensitive drugs within 8 weeks. 5. Participate in any drug clinical trial (as a subject) within 1 month prior to participating in this trial. 6. Severe immunodeficiency. 7. Persons with scar constitution. 8. Persons with known cutaneous photohypersensitivity, porphyria, or allergy to ALA or lidocaine. 9. Those suffering from serious medical, psychological and mental illness, infectious diseases or pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Clearance rate after follow-up;Recurrence rate after follow-up;Number, size, and location of lesions;	—

Secondary

Measure	Time frame
Pain assessment;Incidence of other adverse reactions;Patient satisfaction assessment;	—

Countries

China

Contacts

Public ContactGuolong Zhang

Shanghai Dermatology Hospital

zglamu@163.com+86 18017336835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026